Phase II Study Comparing FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.
Phase 2
18 Years
70 Years
18 Years
70 Years
Not Enrolling
Both
Glioblastoma
Both
Glioblastoma
Trial Information
Phase II Study Comparing FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.
Inclusion Criteria:
1. Post operative patients of documented high grade gliomas (grade III and IV)
2. Patients who have not undergone any previous irradiation to brain.
3. Performance Scale as defined by ECOG PS 0-3
Exclusion Criteria:
1. Patients who are diabetic.
2. Patients who are pregnant.
3. Any documented contrast allergy to the agents used for imaging.
4. Patients who are unable to comprehend or cooperate effectively for treatment
planning.
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Tumor infiltration defined on FDG-PET not determined to MRI
Outcome Time Frame:
18 months
Safety Issue:
No
Authority:
India: Indian Council of Medical Research
Study ID:
AHD1234
NCT ID:
NCT01083719
Start Date:
April 2010
Completion Date:
August 2011
Related Keywords:
- Glioblastoma
- Glioblastoma
- FDG-PET
- MRI
- Glioblastoma
Name | Location |
|---|
